Hypoparathyroidism

What changes during this transition

Hypoparathyroidism is deficient parathyroid hormone (PTH) production leading to chronic hypocalcemia, hyperphosphatemia, low or inappropriately-normal PTH, and impaired activation of vitamin D — PTH normally stimulates osteoclast bone resorption, increases renal calcium reabsorption and phosphate excretion, and drives renal 1α-hydroxylation of vitamin D, so its loss breaks calcium homeostasis across bone, kidney, and gut simultaneously. ETIOLOGIES: post-surgical accounts for roughly 75% of cases — most commonly post-thyroidectomy or post-parathyroidectomy or neck surgery for malignancy; transient post-surgical hypoparathyroidism is more common than permanent (~1–3% of thyroidectomies), with risk higher after re-operative surgery or cancer-related dissection. Autoimmune hypoparathyroidism can be isolated or part of Autoimmune Polyglandular Syndrome Type 1 (APS-1 / APECED, driven by AIRE mutations and presenting with chronic mucocutaneous candidiasis + hypoparathyroidism + Addison's, often in childhood). Genetic causes include DiGeorge syndrome (22q11.2 deletion → thymic and parathyroid agenesis), CASR activating mutations producing autosomal dominant hypocalcemia (ADH), GNA11 and GCM2 mutations, and familial isolated hypoparathyroidism. Infiltrative causes include hemochromatosis, Wilson disease, metastatic infiltration, and radiation. Severe hypomagnesemia impairs PTH secretion and action and is reversible with magnesium correction. Hungry bone syndrome — rapid bone uptake of calcium, phosphate, and magnesium after parathyroidectomy for primary hyperparathyroidism — is a distinct post-surgical entity. PSEUDOHYPOPARATHYROIDISM (PHP) is a distinct disease — it is PTH RESISTANCE from GNAS mutations, NOT PTH deficiency; PTH is HIGH in PHP, low or inappropriately-normal in true hypoparathyroidism. Vitamin D deficiency is also distinguished by HIGH compensatory PTH. CLINICAL FEATURES of chronic hypocalcemia: neuromuscular irritability (paresthesias, carpopedal spasm, Chvostek and Trousseau signs, tetany, laryngospasm, seizures); cardiac (prolonged QT, arrhythmias); cognitive and behavioral (anxiety, depression, cognitive impairment); cataracts (chronic); basal ganglia calcifications with extrapyramidal symptoms; renal stones, nephrocalcinosis, and chronic kidney disease — paradoxically driven by hypercalciuria on conventional therapy; enamel and dental hypoplasia in childhood-onset disease; dry skin, brittle nails, alopecia. CONVENTIONAL THERAPY: oral calcium supplements (1–3 g elemental calcium/day divided) plus ACTIVATED vitamin D — calcitriol (1,25(OH)2 vitamin D) is drug of choice because ergocalciferol and cholecalciferol require 1α-hydroxylase activation, which is PTH-dependent and impaired; alfacalcidol is an alternative. Thiazide diuretics may reduce urinary calcium loss; phosphate restriction and magnesium replacement complete the standard regimen. The central challenge is that achieving normocalcemia without inducing hypercalciuria is difficult, and chronic hypercalciuria drives nephrolithiasis, nephrocalcinosis, and progressive CKD — meaning many patients on conventional therapy still have symptomatic hypocalcemia AND accumulating renal complications. PTH-REPLACEMENT THERAPY — PEPTIDE STANDARD-OF-CARE: TERIPARATIDE (Forteo) is recombinant human PTH(1-34), FDA-approved for osteoporosis and used off-label for hypoparathyroidism (roughly 50% reduction in calcium and active vitamin D doses), though its short half-life (~1 hour) requires multiple daily injections. PTH(1-84) (NATPARA, Shire/Takeda) was full-length recombinant PTH, FDA-approved January 2015 for hypoparathyroidism but WITHDRAWN from the market in 2019 due to a manufacturing issue with silicone particles in cartridges — a compassionate-use program continued for existing patients. PALOPEGTERIPARATIDE (YORVIPATH, Ascendis Pharma) is a recombinant PTH(1-34) prodrug delivered via TransCon technology for sustained once-daily SC dosing; FDA-APPROVED AUGUST 2024 as an adjunct to calcium and vitamin D in adult chronic hypoparathyroidism — the FIRST permanent FDA-approved therapy specifically for hypoparathyroidism, on the strength of the PaTHway Phase 3 trial showing quality-of-life improvements, reduced calcium and active vitamin D requirements, and improved urinary calcium handling. Palopegteriparatide replaces Natpara in modern practice and is a genuinely transformative addition for patients whose hypocalcemia symptoms or hypercalciuria-driven renal complications aren't controlled by conventional therapy. Community-peptide framing reaches into hypoparathyroidism mainly through generic 'tissue healing' (BPC-157), 'bone health' or surgical-recovery framing (CJC-1295 + ipamorelin + tesamorelin via IGF-1 effects on bone turnover), or general-aging positioning (NMN); these substrates address each honestly — none modulates PTH or calcium homeostasis, and the GH-axis peptides specifically warrant coordination-of-care conversation with the managing endocrinologist because added bone-turnover modulation in a tightly-managed calcium balance is uncharacterized. WADA implications: PTH analogs are prohibited as anabolic agents. Hypoparathyroidism is frequently iatrogenic from thyroid-cancer surgery — patients are often navigating cancer surveillance AND lifelong hypocalcemia management simultaneously, and any peptide conversation needs to include the oncology team as well as the endocrinologist. APS-1 affects children and adolescents and runs alongside Addison's adrenal insufficiency, which compounds the management complexity. Resources include the Hypoparathyroidism Association, the Endocrine Society 2016 clinical practice guidelines, hungry bone syndrome management literature, and APS-1 patient communities. Standard-of-care is endocrinologist-managed: conventional calcium + calcitriol baseline, with palopegteriparatide as the FDA-approved PTH-replacement option for adult chronic hypoparathyroidism inadequately controlled on conventional therapy. Sixty-eighth deliberate non-elevation of community peptides.